Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Eltrombopag for the Treatment of Refractory Thrombocytopenia Associated With Connective Tissue Disease

NCT06458803 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06458803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06458803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Eltrombopag for the Treatment of Refractory Thrombocytopenia Associated With Connective Tissue Disease
Lead sponsor
Tongji Hospital
Phase
Observational
Overall status
Completed
Start date
May 6, 2013
Completion date
November 19, 2023
Enrollment
52 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

connective tissue diseases, refractory thrombocytopenia